Interstitial lung disease associated with leflunomide

Internal Medicine

Volumn 43, Issue 12, 2004, Pages 1103-1104

  Ito, Satoshi ^a   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Interstitial lung disease; Leflunomide; Rheumatoid arthritis

Indexed keywords

ACTARIT; BUCILLAMINE; CORTICOSTEROID; GEFITINIB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; LOBENZARIT; METHOTREXATE; SALAZOSULFAPYRIDINE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MAINTENANCE DRUG DOSE; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; PRESCRIPTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; HUMANS; ISOXAZOLES; LUNG DISEASES, INTERSTITIAL;

EID: 11344278662     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.1103     Document Type: Article

References (15)

1. McCurry J. Japan death spark concerns over arthritis dug. Lancet 363: 461, 2004.
2. Scott DL. Interstitial lung disease and disease modifying anti-rheumatic drugs. Lancet 363: 1239-1240, 2004.
3. Ichikawa Y, Kamatani N, Goto M, et al. Phase II dose ranging study of leflunomide in Japan - Investigation of efficacy, safety and pharmacokinetics. J New Rem & Clin 52: 891-931, 2003 (in Japanese).
4. Tateishi H, Ogawa R, Nakamura T, Murata N, Tanaka S. Safety and efficacy of long term treatment of leflunomide in Japanese RA patients. J New Rem & Clin 52: 932-958, 2003 (in Japanese).
5. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis. A double-blind, randomized, multicenter trial. European Leflunomide Study Group. Lancet 353: 259-266, 1999.
6. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 159: 2542-2550, 1999.
7. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39: 655-665, 2000.
8. Cannon GW, Strand V, Scarazzini L. Comparison of adverse event reporting rates for etanercept, infliximab, leflunomide and methotrexate. Arthritis Rheum 48: S242, 2003.
9. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford) 43: 143-147, 2004.
10. Fiechtner J, Ito S, Nakano M, Gejyo F, Hanyu T, Murasawa A. Thoughts on Japanese versus North American rheumatology. J Clin Rheumatol 7: 208-209, 2001.
11. Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunotnide as an adverse reaction. Intern Med 43: 1201-1204, 2004.
12. Guideline for Clinical Evaluation for Anticancer Drugs (PAB/NDD Notification No. 9 dated Feburary 4, 1991.
13. Japanese Periodical Safety Update Report (5 Jul 2002-4 Jan 2004), AstraZeneca K.K. Japan (in Japanese).
14. Forsythe B, Faulkner K. Clinical experience with gefitinib ('Iressa', ZD1839): an overview of safety and tolerability. Lung Cancer 41: 2003 (Abstract of the 10th World Conference on Lung Cancer 10-14 Adjuvant 2003, Vancouver, Canada).
15. Negishi M, Isozaki T, Matsunawa M, et al. Clinical experience of leflunomide (Arava®): J New Rem & Clin 53: 489-493, 2004 (in Japanese).